Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia

NCT03625388 is registered in ClinicalTrials.gov with Hikma Pharmaceuticals LLC as lead sponsor.

NCT NCT03625388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03625388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
Lead sponsor
Hikma Pharmaceuticals LLC
Phase
Phase 2
Overall status
Completed
Start date
November 5, 2018
Completion date
July 22, 2023
Enrollment
56 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia